190 related articles for article (PubMed ID: 36529967)
1. Advances in targeting estrogen synthesis and receptors in patients with endometriosis.
Clemenza S; Vannuccini S; Ruotolo A; Capezzuoli T; Petraglia F
Expert Opin Investig Drugs; 2022 Nov; 31(11):1227-1238. PubMed ID: 36529967
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
Ishihara H; Kitawaki J; Kado N; Koshiba H; Fushiki S; Honjo H
Fertil Steril; 2003 Mar; 79 Suppl 1():735-42. PubMed ID: 12620485
[TBL] [Abstract][Full Text] [Related]
3. Novel pharmacological therapies for the treatment of endometriosis.
Buggio L; Dridi D; Barbara G; Merli CEM; Cetera GE; Vercellini P
Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1039-1052. PubMed ID: 36000243
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for endometriosis.
Fedele L; Berlanda N
Expert Opin Emerg Drugs; 2004 May; 9(1):167-77. PubMed ID: 15155142
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy for endometriosis: from molecular research to bedside.
Tosti C; Biscione A; Morgante G; Bifulco G; Luisi S; Petraglia F
Eur J Obstet Gynecol Reprod Biol; 2017 Feb; 209():61-66. PubMed ID: 27503693
[TBL] [Abstract][Full Text] [Related]
6. From pathogenesis to clinical practice: Emerging medical treatments for endometriosis.
Clemenza S; Sorbi F; Noci I; Capezzuoli T; Turrini I; Carriero C; Buffi N; Fambrini M; Petraglia F
Best Pract Res Clin Obstet Gynaecol; 2018 Aug; 51():92-101. PubMed ID: 29559388
[TBL] [Abstract][Full Text] [Related]
7. Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Kitawaki J
Best Pract Res Clin Obstet Gynaecol; 2006 Aug; 20(4):493-502. PubMed ID: 16564227
[TBL] [Abstract][Full Text] [Related]
8. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
9. Hormonal treatments for endometriosis: The endocrine background.
Vannuccini S; Clemenza S; Rossi M; Petraglia F
Rev Endocr Metab Disord; 2022 Jun; 23(3):333-355. PubMed ID: 34405378
[TBL] [Abstract][Full Text] [Related]
10. A review of phase II and III drugs for the treatment and management of endometriosis.
Perrone U; Evangelisti G; Laganà AS; Bogliolo S; Ceccaroni M; Izzotti A; Gustavino C; Ferrero S; Barra F
Expert Opin Emerg Drugs; 2023 Dec; 28(4):333-351. PubMed ID: 38099328
[TBL] [Abstract][Full Text] [Related]
11. Advances in pharmacotherapy for treating endometriosis.
Tafi E; Leone Roberti Maggiore U; Alessandri F; Bogliolo S; Gardella B; Vellone VG; Grillo F; Mastracci L; Ferrero S
Expert Opin Pharmacother; 2015; 16(16):2465-83. PubMed ID: 26569155
[TBL] [Abstract][Full Text] [Related]
12. Endometriosis and nuclear receptors.
Yilmaz BD; Bulun SE
Hum Reprod Update; 2019 Jul; 25(4):473-485. PubMed ID: 30809650
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.
Barra F; Grandi G; Tantari M; Scala C; Facchinetti F; Ferrero S
Expert Opin Biol Ther; 2019 Apr; 19(4):343-360. PubMed ID: 30763525
[TBL] [Abstract][Full Text] [Related]
14. New medical treatments for endometriosis.
Olive DL; Lindheim SR; Pritts EA
Best Pract Res Clin Obstet Gynaecol; 2004 Apr; 18(2):319-28. PubMed ID: 15157645
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic uses of gonadotropin-releasing hormone analogs.
Andreyko JL; Marshall LA; Dumesic DA; Jaffe RB
Obstet Gynecol Surv; 1987 Jan; 42(1):1-21. PubMed ID: 3543765
[TBL] [Abstract][Full Text] [Related]
16. Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for
Salah M; Tahoun M; Rudzitis-Auth J; Stotz L; van Koppen CJ; Laschke MW; Abdelsamie AS; Frotscher M
J Med Chem; 2023 Jul; 66(13):8975-8992. PubMed ID: 37369108
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors in the pharmacotherapy of endometriosis.
Gardella B; Rispoli E; Pasquali MF; Mauri M; Musacchi V; Dominoni M
Expert Opin Pharmacother; 2023 Jun; 24(9):1067-1073. PubMed ID: 37128968
[TBL] [Abstract][Full Text] [Related]
18. An irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 inhibits estradiol synthesis in human endometriosis lesions and induces regression of the non-human primate endometriosis.
Poirier D; Nyachieo A; Romano A; Roy J; Maltais R; Chai D; Delvoux B; Tomassetti C; Vanhie A
J Steroid Biochem Mol Biol; 2022 Sep; 222():106136. PubMed ID: 35691460
[TBL] [Abstract][Full Text] [Related]
19. Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism.
Mercorio A; Giampaolino P; Romano A; Dällenbach P; Pluchino N
Front Endocrinol (Lausanne); 2022; 13():950866. PubMed ID: 36204107
[TBL] [Abstract][Full Text] [Related]
20. Endometriosis: the pathophysiology as an estrogen-dependent disease.
Kitawaki J; Kado N; Ishihara H; Koshiba H; Kitaoka Y; Honjo H
J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):149-55. PubMed ID: 12650711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
